The aim of this study was to characterize the incidence and risk factors for BRAF inhibitor– and MEK inhibitor–associated hypertension and cancer therapy–related cardiac dysfunction (CTRCD) in a real-world setting. The gene discussed is BRAF; the disease is cancer.